ALCAM and breast neoplasm: Furthermore, a study by Ihnen et al. [55], containing 481 breast tumours has discovered that a subset of the patients with ALCAM(low)/Osteopontin(High)/ER(negative)/Her2(negative) tumours had markedly shorter disease-free and overall survival and that the combination is a strong independent prognostic indicator.